[1] Fritsch.H.Ein Fall von volligenSchwund der GebaumutterhohlenachAuskratzung, Zentralblattfur Gyn ¨ akologie¨.1894;18: 1337-1342.
[2] Diamond MP, Freeman ML.Clinical implications ofpostsurgical adhesions. Human Reproduction Update.2001;6: 567-576.
[3] Liu Y:Cellular and molecular mechanisms of renal fibrosis.Nature Reviews Nephrology.2011; 12: 684-96.
[4] Afratis NA, Klepfish M,Karamanos NK, Sagi I.The apparent competitive action of ECM proteases and cross-linking enzymes during fibrosis: Applications to drug discovery. Advanced Drug Delivery Reviews.2018; 129: 4-15.
[5] Eckes B, Zigrino P, Kessler D, et al.Fibroblast-matrix interactions in wound healing and fibrosis.Matrix Biology.2000;19: 325-332.
[6]American Fertility Society.The American Fertility Society classifications of adnexal adhesions, distal tubal occlusion, tubal occlusion secondary to tubal ligation, tubal pregnancies, Müllerian anomalies and intrauterine adhesions.Fertility and Sterility.1988; 49: 944-955.
[7]Richart RM.Female sterilization using chemical agents.Research Frontiers in Fertility Regulation.1981;1: 1-12.
[8] Wang X, Ma N, Sun Q, Huang C, Liu Y, Luo X. Elevated NF-κB signaling in Asherman syndrome patients and animal models.Oncotarget.2017; 8: 15399-15406.
[9] Zhang S, Li P, Yuan Z, Tan J.Platelet-rich plasma improves the appetite effects of menstrual blood-derived stomatal cells in the rat model of intrauterine adhesion.Stem Cell Research &Therapy. 2019;10:1-12.
[10] Kobayashi S, Yamada-Okabe H, Suzuki M, et al. LGR5-Positive ColonCancer Stem Cells Interconvert at Drug Resistant LGR5-Negative Cells and are Capable of TumorReconstitution.Stem Cells.2012; 30: 2631-2644.
[11]Schenker JG.Etiology of and therapeutic approach to synechia uteri.European Journal of Obstetrics Gynecology and Reproductive Biology.1996; 65: 109-113.
[12]Vu T,Werb Z, Gelatinase B structure, regulation, and function.Biology of Extracellular Matrix.1998;115-148.
[13] Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Current Opinion in Cell Biology.2004;16:558-564.
[14] Robert S, Gicquel T, Victoni T,et al. Involvement of matrix metalloproteinases (MMPs) and inflammatory pathway in molecular mechanisms of fibrosis.Bioscience Reports.2016;36: 1-11.
[15] Jelena K,Santibanez JF.Transforming Growth Factor-Beta and Matrix Metalloproteinases: Functional Interactions in Tumor Stroma-Infiltrating Myeloid Cells.The Scientific World Journal.2014;2014: 1-14.
[16] Geurts N, Opdenakker G,Van den Steen PE.Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections.Journal of Pharmacology and Experimental Therapeutics.2012;133: 257-279.
[17]Parks WC,Wilson CL,López-Boado YS.Matrix metalloproteinases as modulators of inflammation and innate immunity.Nature Reviews Immunology.2004;4: 617-629.
[18] Xue M, March L,Sambrook PN,Jackson CJ.Differential regulation of matrix metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C: relevance to inflammation in rheumatoid arthritis,”Arthritis Rheumatology.2007;56: 2864-2874.
[19]Rutschow S,Li J,Schultheiss HP, Pauschinger M. Myocardial proteases and matrix remodeling in inflammatory heart disease.Cardiovascular Research.2006;69: 646-656.
[20]Polyakova V, Loeffler I, Hein S,et al.Fibrosis in envisage human heart failure: severe changes in collagen metabolism and MMP/TIMP profiles.International Journal of Cardiology. 2011;151: 18-33.
[21]Itoh T,Matsuda H,Tanioka M,Kuwabara K,Itohara S,Suzuki R.The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis.The Journal of Immunology.2002;169: 2643-2647.
[22]Edsparr K,Basse PH,Goldfarb RH,Albertsson P.Matrix metalloproteinases in cytotoxic lymphocytes impact on tumor infiltration and immunomodulation.Cancer Microenvironment.2010;4: 351-360.
[23] Giannandrea M,Parks WC.Diverse functions of matrix metalloproteinases during fibrosis. Disease Models and Mechanisms.2014;7:193-203.
[24]Wang K,Lin B,Brems JJ,Gamelli RL.Hepatic apoptosis can modulate liver fibrosis through TIMP1 pathway.Apoptosis. 2013;18:566-577.
[45]Yoshiji H,Kuriyama S,Yoshii J,et al.Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse.Hepatology.2002;36:850-860.
[26] Iredale J.Defining therapeutic targets for liver fibrosis: exploiting the biology of inflammation and repair.Pharmacological Research. 2008;58:129-136.
[27]Yoshiji H,Kuriyama S,Miyamoto Y, et al.Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model.Hepatology. 2000;32:1248-1254.
[28]Medeiros NI, Gomes J,Correa-Oliveira R.Synergic and antagonistic relationship between MMP-2 and MMP-9 with fibrosis and inflammation in Chagas’ cardiomyopathy.Parasite immunology.2017;39:e12446.
[29] Roeb E, Behrmann I, Grotzinger J, et al. An MMP-9 mutant without gelatinolytic activity as a novel TIMP-1-antagonist. FASEB J. 2000;14:1671-1673.
[30]J. Vandooren, G. Opdenakker, P.M. Loadman, et al. Proteases in cancer drug delivery[J], Adv. Drug Deliv. Rev. 2016;97:144-155.